Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”

Hollis Lin; Sonalee Agarwal; Marissa Betts; Kyle Fahrbach; Madhura Chitnis; Michael Polydefkis

doi:10.1080/14656566.2019.1620987

Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”

Hollis Lin, Sonalee Agarwal, Marissa Betts, Kyle Fahrbach, Madhura Chitnis, Michael Polydefkis

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1529-1530
Number of pages	2
Journal	Expert opinion on pharmacotherapy
Volume	20
Issue number	12
DOIs	https://doi.org/10.1080/14656566.2019.1620987
State	Published - 2019

Keywords

Transthyretin amyloid polyneuropathy
indirect treatment comparison

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1080/14656566.2019.1620987

Cite this

Lin, H., Agarwal, S., Betts, M., Fahrbach, K., Chitnis, M., & Polydefkis, M. (2019). Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. Expert opinion on pharmacotherapy, 20(12), 1529-1530. https://doi.org/10.1080/14656566.2019.1620987

Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. / Lin, Hollis; Agarwal, Sonalee; Betts, Marissa et al.
In: Expert opinion on pharmacotherapy, Vol. 20, No. 12, 2019, p. 1529-1530.

Research output: Contribution to journal › Letter › peer-review

Lin, H, Agarwal, S, Betts, M, Fahrbach, K, Chitnis, M & Polydefkis, M 2019, 'Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”', Expert opinion on pharmacotherapy, vol. 20, no. 12, pp. 1529-1530. https://doi.org/10.1080/14656566.2019.1620987

@article{f4cb23710f0d481cadba91733d45f44c,

title = "Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”",

keywords = "Transthyretin amyloid polyneuropathy, indirect treatment comparison",

author = "Hollis Lin and Sonalee Agarwal and Marissa Betts and Kyle Fahrbach and Madhura Chitnis and Michael Polydefkis",

note = "Funding Information: This work was sponsored by Alnylam Pharmaceuticals, Cambridge, MA, USA.",

year = "2019",

doi = "10.1080/14656566.2019.1620987",

language = "English (US)",

volume = "20",

pages = "1529--1530",

journal = "Expert opinion on pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”

AU - Lin, Hollis

AU - Agarwal, Sonalee

AU - Betts, Marissa

AU - Fahrbach, Kyle

AU - Chitnis, Madhura

AU - Polydefkis, Michael

N1 - Funding Information: This work was sponsored by Alnylam Pharmaceuticals, Cambridge, MA, USA.

PY - 2019

Y1 - 2019

KW - Transthyretin amyloid polyneuropathy

KW - indirect treatment comparison

UR - http://www.scopus.com/inward/record.url?scp=85066912633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066912633&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1620987

DO - 10.1080/14656566.2019.1620987

M3 - Letter

C2 - 31124741

AN - SCOPUS:85066912633

SN - 1465-6566

VL - 20

SP - 1529

EP - 1530

JO - Expert opinion on pharmacotherapy

JF - Expert opinion on pharmacotherapy

IS - 12

ER -

Response to the letter to the editor on “an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this